方法：临床纳入湿性老年性黄斑变性患者70例70眼，根据治疗方案的不同分为研究组与对照组。对照组给予曲安奈德注射液玻璃体腔注射，研究组给予康柏西普注射液玻璃体腔注射。观察两组患者治疗前后裸眼视力变化情况、阅读能力评分、视网膜黄斑色素密度等。

结果：治疗后6mo，1a，研究组视力分别为0.47±0.11、0.60±0.14，对照组视力分别为0.27±0.09、0.30±0.15，两组比较差异有统计学意义(P<0.05)； 治疗后6mo，1a，研究组黄斑中心凹视网膜厚度分别为336.8±65.4、301.5±76.8μm，对照组黄斑中心凹视网膜厚度分别为379.4±88.2、368.6±81.3μm，两组比较差异有统计学意义(P<0.05)； 治疗后6mo，1a，研究组视网膜黄斑色素密度分别为0.19±0.07、0.25±0.09DU； 对照组视网膜黄斑色素密度分别为0.12±0.05、0.14±0.05DU，两组比较差异有统计学意义(P<0.05)。

结论：玻璃体腔注射康柏西普注射液治疗湿性老年性黄斑变性，具有较好的临床效果，能够显著提高患者裸眼视力，值得推广。

METHODS:Seventy patients(70 eyes)with wAMD were selected and divided into study group and control group according to different therapies. The control group received intravitreal injection of triamcinolone acetonide. The study group adopted the intravitreal injection with conbercept. Uncorrected visual acuity, the score of reading ability, the central macular thickness(CMT)and the macular pigment optical density of two groups before and after treatment was observed.

RESULTS: the visual acuity of study group was 0.47±0.11 and 0.60±0.14 respectively at 6mo and 1a after treatments, those of control group were 0.27±0.09 and 0.30±0.15. The differences between the two groups at the two points were statistically significant(P<0.05). The CMT of study group was 336.8±65.4 and 301.5±76.8μm respectively at 6mo and 1a after treatments, those of control group were 379.4±88.2 and 368.6±81.3μm. The differences between the two groups at the two points were statistically significant(P<0.05). The macular pigment optical density of study group was 0.19±0.07 and 0.25±0.09DU respectively at 6mo and 1a after treatments, those of control group were 0.12±0.05 and 0.14±0.05μm. The differences between the two groups at the two points were statistically significant(P<0.05).

CONCLUSION:The intravitreal injection with conbercept has a favorable clinical effect on the treatment of wAMD, Which can greatly improve the uncorrected visual acuity and is worthy promotion.